True Vision MN LLC Boosts Holdings in Hims & Hers Health, Inc. $HIMS

True Vision MN LLC boosted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 3.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,376 shares of the company’s stock after buying an additional 328 shares during the quarter. True Vision MN LLC’s holdings in Hims & Hers Health were worth $467,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of HIMS. Nuveen LLC purchased a new position in Hims & Hers Health during the first quarter worth $58,403,000. Yong Rong HK Asset Management Ltd boosted its stake in shares of Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after purchasing an additional 700,100 shares during the period. CloudAlpha Capital Management Limited Hong Kong purchased a new stake in shares of Hims & Hers Health during the first quarter valued at $20,580,000. Jump Financial LLC boosted its stake in shares of Hims & Hers Health by 633.2% during the first quarter. Jump Financial LLC now owns 725,445 shares of the company’s stock valued at $21,437,000 after purchasing an additional 626,496 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after purchasing an additional 397,310 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on HIMS shares. Canaccord Genuity Group reissued a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a research note on Friday, September 12th. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Truist Financial lowered their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research note on Monday, August 18th. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Finally, Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Stock Performance

HIMS stock opened at $54.68 on Tuesday. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The business has a 50-day moving average price of $51.39 and a 200 day moving average price of $47.49. The company has a market capitalization of $12.36 billion, a P/E ratio of 68.35, a PEG ratio of 3.55 and a beta of 2.25. Hims & Hers Health, Inc. has a 1-year low of $17.36 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business’s revenue was up 72.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares in the company, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 145,000 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the completion of the transaction, the chief financial officer owned 128,984 shares of the company’s stock, valued at $7,139,264.40. This represents a 52.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,611,146 shares of company stock worth $83,026,206. 17.71% of the stock is owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.